Get the Stockscreener App
78.43
3.99%
-3.26
After Hours:
78.43
Henry Schein Inc stock is traded at $78.43, with a volume of 1.87M.
It is down -3.99% in the last 24 hours and up +3.02% over the past month.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.
See More
Previous Close:
$81.69
Open:
$81.78
24h Volume:
1.87M
Relative Volume:
1.53
Market Cap:
$9.23B
Revenue:
$12.50B
Net Income/Loss:
$314.00M
P/E Ratio:
32.14
EPS:
2.44
Net Cash Flow:
$421.00M
1W Performance:
+1.86%
1M Performance:
+3.02%
6M Performance:
+16.19%
1Y Performance:
+1.59%
1-Day Range:
$78.11
$82.80
1-Week Range:
$77.46
$82.80
52-Week Range:
$60.56
$82.80
Henry Schein Inc Stock (HSIC) Company Profile
Name
Henry Schein Inc
Sector
Industry
Phone
(631) 843-5500
Address
135 DURYEA RD, MELVILLE, NY
Compare HSIC vs MCK, COR, CAH, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
78.43 | 9.62B | 12.50B | 314.00M | 421.00M | 2.44 |
|
MCK
Mckesson Corporation
|
916.00 | 116.75B | 397.96B | 4.55B | 9.64B | 34.77 |
|
COR
Cencora Inc
|
351.06 | 71.14B | 325.78B | 1.64B | 3.61B | 8.3139 |
|
CAH
Cardinal Health Inc
|
215.06 | 52.77B | 244.67B | 1.68B | 5.51B | 6.9487 |
|
AHG
Akso Health Group Adr
|
1.44 | 1.21B | 2.22M | -5.63M | -1.68M | -0.24 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-26-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-25-25 | Downgrade | Stifel | Buy → Hold |
| Jul-14-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-14-25 | Initiated | Wells Fargo | Equal Weight |
| Jan-06-25 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Jul-22-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-12-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-10-23 | Upgrade | Stifel | Hold → Buy |
| Aug-08-22 | Upgrade | UBS | Sell → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| Jan-31-22 | Initiated | Morgan Stanley | Underweight |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Oct-01-21 | Resumed | Credit Suisse | Neutral |
| Feb-08-21 | Resumed | Piper Sandler | Overweight |
| Jan-04-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-03-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Apr-07-20 | Upgrade | Goldman | Neutral → Buy |
| Apr-02-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-02-20 | Upgrade | Evercore ISI | Underperform → In-line |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-30-19 | Initiated | Wolfe Research | Underperform |
| May-15-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Jan-17-19 | Initiated | UBS | Sell |
| Jan-03-19 | Downgrade | Evercore ISI | In-line → Underperform |
| Jan-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-08-18 | Reiterated | Barrington Research | Outperform |
| Oct-25-18 | Downgrade | Edward Jones | Hold → Sell |
| Oct-19-18 | Resumed | Goldman | Neutral |
| Oct-04-18 | Reiterated | Robert W. Baird | Outperform |
| Aug-07-18 | Reiterated | Stifel | Hold |
| Apr-24-18 | Downgrade | Goldman | Buy → Neutral |
| Apr-04-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
View All
Henry Schein Inc Stock (HSIC) Latest News
New CEO installed at Henry Schein Inc. - LI Press
Henry Schein (NASDAQ:HSIC) Reaches New 12-Month HighHere's Why - MarketBeat
Henry Schein Celebrates New Dallas Facility - Dentistry Today
Global Shift to Clear Aligners to Build a USD 99.44 Billion Market by 2034 - GlobeNewswire Inc.
Henry Schein, Inc. $HSIC Shares Sold by Nuance Investments LLC - MarketBeat
Assessing Henry Schein (HSIC) Valuation As Growth And Returns Face Competitive Pressure - Yahoo Finance
Henry Schein Leadership Exit Tests Distribution Strength And Competitive Position - Yahoo Finance
Henry Schein stock hits 52-week high, reaching 80.66 USD By Investing.com - Investing.com Canada
Henry Schein (NASDAQ:HSIC) Hits New 1-Year HighHere's What Happened - MarketBeat
Henry Schein stock hits 52-week high, reaching 80.66 USD - Investing.com
Henry Schein, Inc. $HSIC Shares Bought by M.D. Sass LLC - MarketBeat
A Legacy of Brighter Smiles: Celebrating 24 Years of the Give Kids A Smile Program – Company Announcement - Financial Times
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC) and Azenta (AZTA) - The Globe and Mail
Henry Schein, Inc. $HSIC Shares Sold by Strs Ohio - MarketBeat
Henry Schein (BIT:1HSIC) Price Target Decreased by 12.37% to 65.12 - Nasdaq
What Henry Schein (HSIC)'s Activist-Backed Governance Shift and CEO Transition Means For Shareholders - Yahoo Finance
Greenlight Capital Backs Henry Schein As Governance Shifts Target Margins - Yahoo Finance
Assessing Henry Schein’s Valuation After Greenlight Capital’s Push For Operational Improvements - Sahm
How Henry Schein Inc. (HSIC) Affects Rotational Strategy Timing - Stock Traders Daily
Does Henry Schein (HSIC) Have Potential for Margin Improvement and Increased Shareholder Value? - Insider Monkey
Henry Schein, Inc. $HSIC Holdings Lowered by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Briefly: NCPA, Henry Schein Announce New Executive Leaders - HME Business
Analyst Downgrade: Will Henry Schein Inc. benefit from green energy policiesEarnings Beat & Expert Approved Trade Ideas - baoquankhu1.vn
Henry Schein Schedules Q4 2025 Earnings Call - Dentistry Today
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Agios Pharma (AGIO) and Henry Schein (HSIC) - The Globe and Mail
Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET - BioSpace
How Investors Are Reacting To Henry Schein (HSIC) New CEO Pick And Exclusive CitoCBC Deal - simplywall.st
Henry Schein Shares Consolidate as Technical and Fundamental Catalysts Align - AD HOC NEWS
Henry Schein Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
Dilation Capital Management LP Invests $5.11 Million in Henry Schein, Inc. $HSIC - MarketBeat
Henry Schein Names Frederick M. Lowery as Chief Executive Officer - Zenopa
Henry Schein, Inc. (NASDAQ:HSIC) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Henry Schein Inc. Stock Underperforms Tuesday When Compared To Competitors - 富途资讯
The Truth About Henry Schein Inc: Why Wall Street Is Watching (But TikTok Barely Cares…Yet) - AD HOC NEWS
Mizuho Adjusts Price Target on Henry Schein to $81 From $74, Maintains Neutral Rating - marketscreener.com
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Here's What to Expect From Henry Schein's Next Earnings Report - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: Henry Schein (HSIC), Boston Scientific (BSX) - The Globe and Mail
Mixed Strategic Drivers Led Upslope Capital Management to Pick Henry Schein (HSIC) - Insider Monkey
Tetratherix executes global distribution & supply agreement with Henry Schein - marketscreener.com
Tetratherix Executes Global Distribution & Supply Agreement With Henry Schein - TradingView — Track All Markets
Newly listed biotech Tetratherix secures global distribution deal with US giant Henry Schein - Business News Australia
Australia's Tetratherix hits four-week high on supply deal with Henry Schein - TradingView — Track All Markets
Henry Schein (NASDAQ:HSIC) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Henry Schein names new CEO - DrBicuspid.com
Henry Schein (HSIC) Valuation Check After Exclusive CitoCBC Distribution Agreement - Yahoo Finance
Henry Schein inks exclusive U.S. distribution deal for CLIA-waived CBC system - Medical Economics
Henry Schein enters distribution agreement for CytoChip's CLIA-waived hematology analyzer - marketscreener.com
Henry Schein Enters Distribution Agreement For CytoChip’S CLIA-Waived Hematology Analyzer - TradingView — Track All Markets
Henry Schein Agrees to Distribute CytoChip's CitoCBC system - marketscreener.com
Henry Schein Inc Stock (HSIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.13%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):